Testosterone for Women: Benefits, Doses, and How It Compares to Estradiol Therapy

Do Women Actually Have Testosterone?

Women produce testosterone in both the ovaries and adrenal glands, with premenopausal serum levels typically running 15 to 70 ng/dL, roughly one-tenth of male concentrations but biologically meaningful at that range. Production begins falling in the late 30s and accelerates after surgical menopause, dropping 40 to 50% within 24 hours of bilateral oophorectomy [1]. Even without surgery, natural menopause reduces androgen output substantially because the postmenopausal ovary still secretes testosterone, but falling LH stimulation blunts that output over time [2].

Testosterone in women binds to androgen receptors in the brain, clitoris, vaginal wall, bone, and skeletal muscle. Low levels associate with decreased genital sensation, reduced motivation, and a diminished sexual response cycle. The 2019 ISSWSH position statement defines testosterone therapy as having "sufficient evidence to support efficacy and safety for the treatment of HSDD in postmenopausal women" when used within physiologic female ranges [3].

This is not a fringe or experimental claim. The Global Consensus Statement on the Use of Testosterone Therapy for Women, published simultaneously in the Journal of Sexual Medicine, Climacteric, and other major journals in 2019, included endorsement from 10 international medical societies [4].

The Evidence Base: What Clinical Trials Actually Show

The most cited controlled data come from the Intrinsa transdermal testosterone patch program (300 mcg/day), studied in surgically menopausal women with HSDD. The INTIMATE SM1 trial (N=533) showed a statistically significant increase in satisfying sexual events (SSEs): women on the testosterone patch gained a mean 2.1 additional SSEs per 4-week period versus 0.98 for placebo (P<0.0001) [5]. The INTIMATE NM1 trial replicated those findings in naturally menopausal women [6].

A 2019 systematic review and meta-analysis by Davis et al. (18 RCTs, N=3,176) found that testosterone therapy significantly improved sexual function across all domains measured by the Female Sexual Function Index (FSFI), with a standardized mean difference of 0.42 (95% CI 0.30, 0.54) for satisfying sexual events compared with placebo [7]. The same analysis found no significant increase in acne, hair growth, or adverse cardiovascular events at physiologic doses over study periods up to 24 months.

Bone density data are more limited. A 12-month RCT by Shifren et al. showed that testosterone (150 or 300 mcg/day transdermally) added to standard estrogen therapy did not significantly alter lumbar spine BMD beyond what estrogen alone provided [8]. Testosterone is not yet recommended as a standalone bone-protective agent in women.

The following tiered decision framework summarizes when to add testosterone to a woman's HRT regimen versus optimizing estradiol delivery first. It is intended as a clinical reference for the HealthRX prescribing review process, not as a substitute for individual patient assessment.

Tier 1 (Address First): Rule out untreated vaginal atrophy, thyroid dysfunction, depression, and suboptimal estradiol levels before attributing low libido to androgen deficiency alone.

Tier 2 (Optimize Estradiol): Select the estradiol delivery route (oral, patch, gel, or spray) that best matches the patient's VTE risk, lifestyle, and GI absorption profile. Bring serum estradiol to 40, 100 pg/mL before assessing residual libido complaints.

Tier 3 (Add Testosterone): If HSDD persists after 8 to 12 weeks on optimized estradiol and progesterone, measure serum total testosterone. If below 15 ng/dL with consistent symptoms, initiate low-dose transdermal testosterone at 0.5 to 1 mg/day and reassess at 6 weeks.

Tier 4 (Discontinue or Adjust): If no measurable benefit appears within 6 months, discontinue. If supraphysiologic levels develop at any point, reduce dose immediately.

Dosing and Delivery: Practical Details

No testosterone product carries an FDA approval specifically for women in the United States. Clinicians use compounded testosterone creams or gels (typically 0.5 to 2 mg/day transdermal), or in some cases off-label prescribing of male formulations diluted to female-range doses [9]. The Testosterone Pellet is also used but carries higher risk of prolonged supraphysiologic levels because pellet dosing cannot be reversed once implanted.

Typical protocols at HealthRX involve:

• Compounded testosterone cream 1%: 0.5 to 1 mg applied to inner labia, clitoris, or inner arm daily
• AndroGel 1.62% (off-label, diluted): 1/8 pump (roughly 1.25 mg testosterone) applied to inner arm, rotating sites
• Testosterone cypionate injection (rarely): 2 to 5 mg/week subcutaneous, for patients who cannot absorb transdermal preparations reliably

Monitoring at 4 to 6 weeks post-initiation should target serum total testosterone in the 30 to 60 ng/dL range, within normal premenopausal female physiology. SHBG levels are worth checking concurrently because high SHBG (common in women taking oral estradiol) lowers free testosterone even when total levels appear adequate [10].

Estradiol Delivery Routes and How They Interact With Testosterone Therapy

The choice of estradiol delivery form directly affects the testosterone pharmacokinetics in a woman taking both hormones. Oral estradiol raises SHBG substantially, which can bind free testosterone and reduce its bioavailability. Transdermal estradiol routes have minimal effect on SHBG at standard doses [11]. That single pharmacokinetic difference is why many clinicians prescribe transdermal estradiol when testosterone is also part of the protocol.

Oral Estradiol

Oral estradiol (estradiol tablets, 0.5 to 2 mg/day) undergoes first-pass hepatic metabolism, converting a large fraction to estrone. That hepatic pass also stimulates increased synthesis of SHBG, clotting factors, and angiotensinogen. The Women's Health Initiative Observational Study found that oral estrogen users had a 2- to 4-fold higher risk of venous thromboembolism compared with non-users, while transdermal users showed no significant increase [12]. For women with a personal or family history of VTE, oral estradiol is generally avoided.

Still, oral estradiol suits patients who prefer a daily pill and have no VTE risk factors. Doses of 0.5 to 1 mg/day are commonly used as starting points, with titration guided by symptom response and a target serum estradiol of 40, 100 pg/mL.

Estradiol Patch (Vivelle-Dot, Climara)

Transdermal patches deliver estradiol continuously through the skin, bypassing hepatic first-pass metabolism entirely. The Vivelle-Dot patch changes twice weekly (every 3 to 4 days); Climara changes once weekly. Available doses range from 0.025 mg/day to 0.1 mg/day.

A 2010 French cohort study (the E3N cohort, N=80,377) found no elevation in VTE risk with transdermal estradiol compared with non-users (OR 1.0 to 95% CI 0.7, 1.5), in contrast to the elevated risk seen with oral conjugated equine estrogen [13]. Patch users also avoid the SHBG elevation that compromises free testosterone bioavailability.

Skin irritation at the adhesive site affects roughly 5 to 10% of patch users and is the most common reason patients switch delivery forms. Rotating sites and ensuring clean, dry skin before application reduces that rate.

Estradiol Gel (Divigel 0.1%)

Divigel 0.1% estradiol gel contains 0.25 mg, 0.5 mg, or 1 mg of estradiol per unit-dose packet, applied to the upper thigh daily. Being a transdermal gel, it shares the same favorable VTE and SHBG profile as the patch. Clinical trial data submitted for FDA approval demonstrated that 0.5 mg/day Divigel reduced moderate-to-severe hot flashes by 73% versus 51% for placebo (P<0.001) at 12 weeks [14].

Patients who find the patch adhesive irritating often do well on Divigel. The main caution is transfer: wet gel on the thigh can transfer to a partner or child through skin contact before it dries, typically within 2 to 5 minutes of application. Women taking testosterone alongside Divigel should apply the products to different anatomical sites and allow each to dry fully before contact.

Estradiol Topical Spray (Evamist)

Evamist delivers 1.53 mg of estradiol per actuation, applied to the inner forearm. Standard starting dose is 1 spray/day with titration to 2, 3 sprays/day based on symptom response. Each spray deposits a metered dose of alcohol-based solution that dries within 2 minutes.

The FDA-approval key trial for Evamist (N=454 to 12 weeks) showed a statistically significant reduction in the frequency of moderate-to-severe hot flashes by week 12: the 3-spray group averaged 7.5 fewer hot flashes per day versus 3.8 fewer for placebo (P<0.0001) [15]. Like other transdermal formulations, Evamist avoids the SHBG and clotting-factor elevation seen with oral routes.

Transfer risk exists with Evamist as well. The FDA added a boxed-warning addendum in 2008 noting reports of premature pubic hair development in young children who had skin-to-skin contact with application sites on treated adults [16]. Women should cover the forearm or avoid child contact for at least 60 minutes post-application.

Safety Considerations for Testosterone in Women

The most commonly cited concerns about testosterone therapy in women center on androgenic side effects, cardiovascular risk, and breast cancer risk.

Androgenic side effects appear to be dose-dependent. At physiologic doses (targeting 30 to 60 ng/dL serum total testosterone), the Davis 2019 meta-analysis found no statistically significant increase in acne, hirsutism, or alopecia versus placebo over 24 months [7]. Supraphysiologic doses, especially from pellets, have been associated with acne, clitoral hypertrophy, voice deepening (which may be irreversible), and male-pattern hair loss.

Cardiovascular effects at physiologic female doses do not appear harmful based on current data. The 2019 Global Consensus Statement noted no increased risk of adverse cardiovascular events in RCT data reviewed, though long-term controlled trials (beyond 2 years) are still absent [4].

Breast cancer risk remains the most contested question. Observational data are inconsistent. The Global Consensus Statement concluded that "testosterone at doses used in evidence-based practice is unlikely to increase breast cancer risk," while also acknowledging that definitive evidence is lacking [4]. The Million Women Study did not separately analyze testosterone, limiting applicability. Women with a personal history of hormone-receptor positive breast cancer should discuss this risk carefully with their oncologist before starting testosterone.

Lipids: Oral testosterone (rarely used) lowers HDL cholesterol. Transdermal testosterone at physiologic female doses has minimal effect on the lipid panel in most RCT data [7].

Who Is and Is Not a Candidate

A woman may be a candidate for testosterone therapy if she has:

• A diagnosis of HSDD with consistent and distressing symptoms
• Normal thyroid function, no untreated depression, and no reversible cause identified
• Serum total testosterone below 15 ng/dL (or low-normal with low free testosterone and high SHBG)
• No active or recent hormone-receptor positive breast cancer
• No plans for pregnancy (testosterone is teratogenic and must be stopped before conception is attempted)

Women who use testosterone should use reliable contraception if they are not confirmed postmenopausal, because testosterone does not suppress ovulation and inadvertent pregnancy with ongoing testosterone exposure carries fetal risk [4].

Monitoring Protocol

The ISSWSH 2019 position statement and the Global Consensus Statement both recommend measuring serum total testosterone before starting, at 4 to 6 weeks after any dose change, and every 6 months during steady therapy [3][4]. Free testosterone measurement by equilibrium dialysis is more accurate than calculated free testosterone but is not always available; total testosterone with SHBG offers a workable clinical proxy.

If levels exceed 70 ng/dL (the upper limit of normal for premenopausal women) on two consecutive measurements, dose should be reduced, even in the absence of androgenic symptoms. Asymptomatic supraphysiologic levels still carry risk over time. Hematocrit should be checked annually given testosterone's mild erythropoietic effect, though polycythemia is far less common in women than in men on TRT.

Combining Testosterone With Progesterone

Women with an intact uterus taking estradiol need progestogen to protect the endometrium from estrogen-driven hyperplasia. Micronized progesterone (Prometrium 100 to 200 mg/night) is the preferred agent in most current guidelines, including the Menopause Society (NAMS) 2023 hormone therapy position statement, because it does not appear to carry the same elevated breast cancer risk seen with synthetic progestins in the WHI trial [17]. Progesterone does not meaningfully affect testosterone levels or free androgen bioavailability at standard doses.